Molecule GEN
An integrated AI-driven SaaS platform for end-to-end in-silico computational drug discovery that enables researchers to translate ideas into therapeutic candidates.
Molecule GEN is a cloud-based SaaS platform for AI-driven drug discovery that automates and accelerates the computational drug design workflow. It provides built-in intelligence and heuristics allowing researchers of varying skill levels to perform de novo target-aware molecule generation, AI-enhanced virtual screening, ADMET property prediction, lead optimization via generative AI, molecular dynamics simulation, and interactive molecule design. The platform offers tailor-made workflows for rational and AI-based de novo drug design, access to curated molecular building block libraries, and continuously updated generative models. It eliminates complex infrastructure setup, letting researchers focus on innovation.
Use cases
De novo generation of target-aware drug-like small molecules
Virtual screening to identify promising molecular candidates
ADMET and drug-likeness property prediction before lab testing
Hit-to-lead and lead optimization through generative AI
Integrations
Cloud-based SaaS (accessible at app.moleculeai.com)
Expected outcomes
Accelerated drug discovery timelines through computational automation
Reduced dependency on manual wet-lab processes in early-stage discovery
Improved decision-making through AI-driven molecular property prediction
Reviews
GCC buyer feedback
Reviews are written by GCC buyers and published after moderation.
No reviews yet
Buyer reviews will appear here once published.
Company
Functions
Engineering & DevOpsData & Analytics
Industries
Healthcare & Life Sciences
1
Integrations
4
Use cases
Is this your company? Claim & customize your profile
This profile was created using publicly available information.